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4.39), sexual contact to a diseased partner and substance 
dependency (all p < 0.001). PTB was associated with male 
sex, low body weight (p < 0.0001), alcoholism (15.0 vs 
5.9%; p < 0.0001), glucocorticoid therapy (7.2 vs 2.0%; 
p = 0.004) and diabetes (7.8 vs. 4.0%; p = 0.04). No con-
tact developed active tuberculosis within 2 years follow-up.
Conclusions Positive IGRA responses are frequent among 
exposed HHCs and HCWs in Germany and are poor pre-
dictors for the development of active tuberculosis.
Keywords LTBI · Incidence · Diabetes mellitus · IGRA · 
Health care workers · Household contacts
Abbreviation
AFB  Acid fast bacilli
BCG  M. bovis Bacillus Calmette-Guérin
BMBF  Bundesministerium für Bildung und Forschung
BMI  Body mass index
EEA  European Economic Area
EU  European Union
HCW  Healthcare worker
Abstract 
Purpose Few individuals that are latently infected with M. 
tuberculosis latent tuberculosis infection(LTBI) progress 
to active disease. We investigated risk factors for LTBI and 
active pulmonary tuberculosis (PTB) in Germany.
Methods Healthy household contacts (HHCs), health care 
workers (HCWs) exposed to M. tuberculosis and PTB 
patients were recruited at 18 German centres. Interferon-γ 
release assay (IGRA) testing was performed. LTBI risk 
factors were evaluated by comparing IGRA-positive with 
IGRA-negative contacts. Risk factors for tuberculosis were 
evaluated by comparing PTB patients with HHCs.
Results From 2008–2014, 603 HHCs, 295 HCWs and 
856 PTBs were recruited. LTBI was found in 34.5% of 
HHCs and in 38.9% of HCWs. In HCWs, care for cough-
ing patients (p = 0.02) and longstanding nursing occu-
pation (p = 0.04) were associated with LTBI. In HHCs, 
predictors for LTBI were a diseased partner (odds ratio 
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HHC  Household contact
IGRA  Interferon-gamma release assay
IPT  Isoniazid preventive therapy
IQR  Interquartile range
IVDU  Intravenous drug use
LTBI  Latent tuberculosis infection
OR  Odds ratio
PTB  Pulmonary tuberculosis
SD  Standard deviation
TB  Tuberculosis
TST  Tuberculin skin test
UK  United Kingdom
WHO  World Health Organisation
Introduction
Tuberculosis incidence has declined in Western Europe 
[1]. In 2014, the notified incidence in the European Union 
and European Economic Area (EU/EEA) was 14.2 cases 
per 100,000 population [1], in some countries only 5 cases 
per 100,000 [1]. Aiming at further reduction, the WHO 
advocated a target tuberculosis incidence of <1 cases per 
1,000,000 in low incidence countries, i.e. the consensual 
tuberculosis elimination threshold [2].
Tuberculosis prevention relies on early case finding 
and on the identification of persons latently infected with 
Mycobacterium tuberculosis (LTBI) [3]. LTBI is defined 
by a positive response to the tuberculin skin test (TST) or 
an interferon-release assay (IGRA) without tuberculosis 
associated symptoms or signs. It is unclear whether the test 
results reflect viable bacilli in the human host. False posi-
tive results can be found, especially in populations of low 
prevalence.
Approximately 9% of healthy persons in Western 
Europe have a positive TST or IGRA test result [4]. If the 
whole population was screened with subsequent preven-
tive chemotherapy for all who tested positive, the number 
needed to treat to prevent one case would not be cost effec-
tive. LTBI screening and treatment is, therefore, only per-
formed in populations with an a priori higher risk for the 
disease [5], e.g. house hold contacts.
Contact tracing identifies 16–44% of close household 
contacts of contagious patients with LTBI [6, 7]. Never-
theless, only a small fraction develops active tuberculosis 
despite the absence of preventive chemotherapy [8]. Pre-
dictive markers of progression to active tuberculosis are 
lacking. The number of latently infected contacts requiring 
preventive chemotherapy to prevent a single case of tuber-
culosis is >1:30 in Western Europe [8]. Adherence to rec-
ommendations for preventive chemotherapy is poor in Ger-
many [9].
To improve prevention and to target individuals for pre-
ventive chemotherapy more precisely, additional knowl-
edge of risk factors for of LTBI and tuberculosis is needed. 
Therefore, our consortium collected epidemiological and 
clinical data from pulmonary tuberculosis (PTB) patients 
and close contacts.
Methods
This observational, multicentre, prospective study was con-
ducted by the German research consortium on “pulmonary 
tuberculosis—host and pathogen determinants of resistance 
and disease progression—(TB or not TB)”. It was approved 
by the ethics committee of the University of Lübeck (refer-
ence 07–125) and adopted by the ethics committees of all 
18 participating centres.
Household contacts (HHCs) were recruited at three 
municipal healthcare centres (Frankfurt, Hamburg, Hanno-
ver). They were suitable for enrolment if they were asymp-
tomatic with no signs of tuberculosis on chest X-ray, were 
exposed >8 h to patients with acid-fast bacilli (AFB) in the 
sputum or >40 h in AFB negative, culture-confirmed PTB. 
Their last unprotected exposure was ≥8 weeks prior to 
enrolment.
Healthcare workers (HCWs) with ongoing professional 
contact to patients with AFB sputum smear-positive tuber-
culosis, a cumulative exposure of ≥2 years, and no signs 
or symptoms of tuberculosis were recruited at 18 German 
respiratory medicine centres.
Patients with current or previous PTB that was culture 
confirmed from sputum or a broncho-pulmonary specimen 
were enrolled. Patients were excluded if they were prison 
inmates, subjects under guardianship or soldiers as this 
interferes with their informed consent.
Clinical and demographic data were captured on an ad 
hoc standardised questionnaire.
This questionnaire was amended during the first 3 years 
resulting in some data on medical and social risk factors. 
IGRAs were performed on blood from contact persons by 
the QuantiFERON Gold In-Tube® (QFT; Cellestis Qia-
gen, Australia) or T-Spot.TB® (Elispot; Oxford Immuno-
tec, Oxford, UK) at the physician’s discretion. TST was 
not regularly performed since national recommendations 
regarding the use of the TST were amended during the 
study [10].
At the start of the study, a two-step approach was recom-
mended involving both, TST and IGRA but TST was aban-
doned in 2011. The study protocol required an obligatory 
IGRA and an optional TST.
After 2 years, HHCs were followed up by health author-
ities; HCWs by a study physician. A questionnaire was sent 
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to the participants. Notified tuberculosis cases would have 
been reported by the participating health authorities.
Statistical analyses
Variables were described using relative frequencies (per-
centages) and means (standard deviations—SD) or medians 
(interquartile ranges—IQR) according to their parametric 
distribution, respectively.
Chi-squared test and student t test or Mann–Whitney 
U test were applied appropriately to assess significant dif-
ferences. Appropriate univariate and multivariate logistic 
regression analyses were performed.
Two-tailed p values <0.05 were considered significant. 
Analyses were carried out with STATA®13 software (Stata-
Corp, College Station, TX, USA).
Results
From December 2008 to December 2014 we recruited 
1754 individuals, i.e. 603 HHCs, 295 HCWs, and 856 PTB 
patients (Table 1). 81 HHCs and 15 HCWs were excluded 
from further analyses due to a missing IGRA result. Among 
contact persons (Table 2), HCWs were older than HHCs 
(mean ± SD: 48.0 ± 5.0- vs 40.6 ± 9.3 years; p < 0.0001), 
were less likely to smoke (23.5 vs 46.4%; p < 0.0001), 
more likely to be female (88.0 vs 53.6%; p < 0.0001), and 
to be born in Germany (88.4 vs 53.2%; p < 0.0001) by a 
German mother (85.9 vs 43.6%; p < 0.0001). An IGRA 
result was available in 522 HHCs and 280 HCWs, of which 
180 (34.5%) and 109 (38.9%) had a positive result, respec-
tively. IGRA results had no gender preference. The propor-
tions of males were 47.8 vs 45.6% (p = 0.64) among HHCs 
and 21.3 vs 22.5% among HCWs (p = 0.82) with a positive 
vs. negative IGRA result, respectively. Most of the initial 
patients had a TST, but due to changed recommendations, 
later patients did not necessarily undergo skin testing. 
Policy changes were adapted by the centres with variable 
delay. For HCWs, neither a well-defined period of expo-
sure nor the moment of last unprotected exposure could be 
determined. Preventive therapy is not recommended in this 
setting; therefore, no data about preventive chemotherapy 
was obtained. Most HHCs were recruited about 6–8 weeks 
after their last unprotected exposure, i.e. before isoniazid 
preventive therapy (IPT) was initiated. Therefore, data on 
IPT was only available in about one-third of the individu-
als. IPT was administered more often in IGRA-positive 
persons (11 out of 59 subjects; 18.6%) than IGRA-nega-
tive subjects (3 out of 109 subjects, 2.8%; p < 0.0001). No 
contact person developed active tuberculosis during the 
two-year follow-up. Follow-up data was available for 241 
HCWs and 171 HHCs.
While a univariate analysis suggested that the rate 
of IGRA positivity increased with age in the HHCs and 
HCWs, this was not confirmed in a multivariate logistic 
regression analysis (Odds ratio 0.99, 95% confidence inter-
val 0.97–1.02; Supplementary material Table 3). IGRA 
positivity was independent of the person’s migration back-
ground. Among the HHCs, IGRA positivity correlated with 
the size of a simultaneous TST, while previous positive 
TSTs as reported by HHCs did not predict a positive IGRA. 
In the HCWs, IGRA positivity was more likely in persons 
Table 1  Numbers of study subjects from participating centres




Number of HHCs Number of PTBs
Hamburg municipal health 
authority
154 47
Frankfurt municpal health 
authority
271 132
Hannover municipal health 
authority
149 97
Research Center Borstel 29 See below
Total 603 276




HELIOS Klinikum, Berlin 40 5
Klinikum Nürnberg 19 28
Lungenklinik Hemer 8 0
Asklepios München-Gauting 26 245
Thoraxklinik UK Heidelberg 0 12
Fachkrankenhaus Coswig 8 41
Klinik Bad Lippspringe 0 0
Lungenklinik Lostau 21 0
Pneum.Klinik Greifenstein 30 20
Klinik Donaustauf 25 7
Klinikum Hannover 9 0
Fachklinik, Parsberg 16 0
Klinik Schillerhöhe Gerlingen 0 0
KKH Diekholzen 9 8
Klinik St. Blasien 1 0
Ev. Lungenklinik Berlin 6 3
Klinik Amsee, Waren 0 0
Research Center Borstel 11 87
Lungenklinik Rotenburg 19 5
Krankenhaus Großhansdorf 12 42
MH Hannover 8 0
KH Solingen 11 31
Dortmund 0 15
Total 280 580
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who reported a positive previous TST (86.5%) than in sub-
jects who reported a negative previous skin test (53.3%; p 
value <0.0001) (Table 2).
The strongest predictor for LTBI after domestic expo-
sure (Supplementary material Table 3) was a partner with 
PTB (OR 4.39, 95% CI 1.88–10.26). The univariate anal-
ysis suggested that a diseased sibling was also associated 
with LTBI (OR 3.23, 95% CI 1.51–6.90), but this was not 
confirmed in the multivariate logistic regression analysis 
(OR 1.23; 95% CI 0.28–5.36). Sexual contact with the part-
ner increased the prevalence of LTBI from 30.8% (no sex) 
to 53.3% (sexual activity). Other factors associated with a 
positive IGRA result among HHCs were a history of previ-
ous tuberculosis (4.5 vs 0.3%; p = 0.001), IVDU (13.5 vs 
1.2%; p < 0.0001), and alcohol dependency (13.5 vs 1.8%; 
p = 0.0001).
For the HCWs, exposure to family members with PTB 
was not associated with LTBI, underlining the focus on pro-
fessional exposure. Caring for coughing patients (p = 0.02) 
and a duration of >20 years of occupation (p = 0.004) were 
associated with LTBI, while the use of respirators, surgi-
cal masks, negative pressure rooms or white coats were not 
(Table 2).
Patients with PTB born in Germany (n = 433) were 
older than tuberculosis patients born abroad (n = 422) with 
a mean (±SD) age of 51.8 (±16.2) vs. 42.4 (±15.1) years 
at diagnosis (p < 0.0001). Uninfected and latently infected 
HHCs showed a balanced gender distribution but PTB was 
more prominent in men (n = 568, 66.4%). Foreign-born TB 
patients were more likely to live in an urban environment 
(90.7%) than Germany born patients (70.6%; p < 0.0001). 
Domestic exposure to a diseased partner or child increased 
the risk of LTBI. In patients with PTB, grandparents 
(9.1%), partners (8.4%) and fathers (8.0%) were most fre-
quently ill. Children (6.0%) and mothers (5.0%) were less 
affected.
Former tuberculosis patients had a lower body mass 
index (BMI) at enrolment than HHCs (mean ± SD, 
22.9 ± 5.0 vs 25.2 ± 4.8 kg/m2; p < 0.0001), and 21.2% 
of tuberculosis patients were underweight. Compared 
to HHCs, the most prevalent medical risk factors for 
active disease included alcohol dependency (15.0 vs 
5.9%; p < 0.0001), glucocorticoid therapy (7.2 vs 2.0%; 
p = 0.004), and diabetes mellitus (7.8 vs 4.0%; p = 0.04). 
Of the diabetic patients, 47% were born outside Germany, 
mirroring the percentage of foreign-born subjects in the 
whole cohort (49%). Less prominent risk factors were 
immunosuppressive treatments, TNF-antagonists therapy, 
chronic renal failure and HIV infection. IVDU was a strong 
risk factor for LTBI but was not for PTB.
Fewer patients with PTB were vaccinated with M. bovis 
Bacillus Calmette-Guérin (BCG) than HHCs (44.6 vs 
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Discussion
We identified additional risk factors for LTBI and active 
pulmonary tuberculosis among HHCs in Germany, a coun-
try of low tuberculosis incidence. Our finding that active 
PTB was reported more frequently in subjects from an 
urban environment may be seen as a confounding factor. It 
reflects the demographic structure of German cities, where 
immigrants in prospering economic regions and cities con-
tribute 9.8–13.4% of the population, compared to 2.8–6.3% 
in smaller and rural centres [11]. Active PTB was more fre-
quent in males, underweight individuals, patients on gluco-
corticoid therapy, diabetic patients, and individuals residing 
in an urban setting. LTBI was most frequently found among 
family members of patients with PTB, especially when a 
partner was affected with whom an active sexual relation-
ship existed. LTBI was more prevalent with alcohol and 
IVDU. In HCWs, only an exposure of more than 20 years 
was associated with LTBI, while no impact from measures to 
prevent transmission was found. Of note, there is no stand-
ardised protocol for the prevention of transmission in Ger-
many. Most centres use FFP2 respirators for staff and surgi-
cal masks for patients. Some staff use a respirator for more 
than one occasions, some change after every patient contact. 
Negative pressure isolation is available in very few centres.
Although follow-up was incomplete with 81.6% of 
enrolled HCWs and 28.4% of HHCs, no contact person 
developed active tuberculosis within 2 years after exposure, 
supporting the poor predictive value of IGRA tests found in 
other trials [8, 12].
In HCWs, only two risk factors for LTBI were identifi-
able: caring for coughing patients and a longstanding occu-
pational exposure. This is in line with Indian data from a 
cohort of nursing students. Christopher et al. found that the 
duration of caring for tuberculosis patients (OR = 1.10; 
95% CI 1.04–1.17) and having performed or assisted in 
sputum collection (OR = 3.57; 95% CI 1.07–11.84) were 
both significantly associated with TST conversions [13].
In our study, LTBI was found in almost 40% of staff 
from tuberculosis wards, exceeding the reported frequency 
in non-specialised nurses in Germany (5.7–8.3%) and 
France (15.5%) [14, 15] and Portugal (30.5 %) [15]. LTBI 
remained even more prevalent than in older non-special-
ised nurses (>55 years) from Germany (25%) or France 
(33.3%). Only in Portuguese nurses aged ≥45 years, a 
prevalence of more than 45% was seen, reflecting the 
higher prevalence of 25/100.000 in Portugal compared to 
5–6/100.000 in Germany and France. Our data indicate that 
in this well-defined, highly exposed population a migration 
background has no significant impact on the IGRA status 
and exposure abroad becomes less relevant.
Our study also provides data on LTBI with implications 
for domestic contact tracing. Of all positive IGRA test 
results, 55% were found in contacts exposed to a diseased 
sibling or partner. Sexual activity with the partner increased 
the probability for LTBI above 50%. Currently, close moni-
toring of intimate contact persons is recommended but 
inquisition about a sexual relationship may refine the focus 
on individuals at risk [10]. In keeping with a recent Nor-
wegian study [16], our analyses support a tracking strategy 
involving core family members first and farther contact 
persons second, complementing current algorithms based 
mainly on proximity and cumulative exposure time [10, 
17]. Despite the poor predictive value of a positive IGRA 
test for the development of active tuberculosis, core contact 
persons may require a close follow-up [8].
The data also suggest that outside the domestic setting, 
contacts with substance dependencies warrant thorough 
investigations due to their increased risk for LTBI. This is 
in keeping with earlier data comparing IGRA with TST 
[18]. However, this finding may be population specific, as 
IVDU appears not to be a risk for LTBI among US prison 
inmates [19]. Alcohol consumption is associated with both, 
higher rates of active tuberculosis and medication induced 
hepatotoxicity—each requiring particular attention after 
exposure [20].
Surprisingly, IVDU was not associated with active 
tuberculosis. The correlation of IVDU and LTBI is known 
from an observational study from Estonia and Latvia and 
from an observational study in the United States (adjusted 
OR = 1.34) [21, 22]. Studies suggesting an association 
between IVDU and active tuberculosis were mostly small, 
confounded by HIV-infection or lacking control groups 
[23–28]. According to our data, IVDU is no independent 
risk factor for the development of active tuberculosis but 
rather a surrogate marker for precarious social conditions.
This study shows an increased prevalence of tubercu-
losis in patients with diabetes mellitus in Germany. While 
there was no correlation in LTBI, the prevalence of diabetes 
nearly doubled from 4.0% in HHCs to 7.8% in patients with 
PTB. This phenomenon was found in both foreign-born 
and Germany born individuals. Patients with PTB were 
older than HHCs but a multivariate analysis did not detect 
an age bias. These data require future evaluation. Until 
now, the epidemiology was considered to be comparable to 
neighbouring countries like Denmark or Poland, where no 
association of tuberculosis and diabetes was found [29, 30]. 
The relationship is not widely acknowledged by German 
physicians although evidence is accumulating for various 
other ethnic groups [31–35].
A limitation of our study is the lack of information on 
preventive chemotherapy in contact persons. A small num-
ber of subjects was offered chemotherapy at the time of 
recruitment, nevertheless no subject developed active tuber-
culosis. The poor uptake of preventive chemotherapy has 
been previously described in Germany [9]. It is associated 
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with the de-centralized management of contact persons 
who are followed up in the health authority offices of 295 
German districts.
Another limitation is that the questionnaires were not 
verified independently. Some data are based on subjective 
perception. While recruitment of HCWs and HHCs was 
prospective, recruitment of patients with PTB was pro-
spective (i.e. patients with active tuberculosis or ongoing 
antimycobacterial therapy) and retrospective (i.e. patients 
who were cured from tuberculosis at enrolment). The three 
cohorts were, therefore, independent and not related to 
each other. This impairs conclusions about cause and effect 
of PTB on the identified variables. Although participants 
were recruited from 18 hospitals and 3 health authorities, 
the data may not be representative for the whole country. 
However, given the large number of enrolled individuals, 
the study provides valid information for risk factors of 
LTBI and active tuberculosis in a Western European coun-
try of low tuberculosis incidence.
In conclusion, our study identified risk groups for LTBI 
and active tuberculosis based on national epidemiologic 
data as suggested in the latest global strategy plan for 
tuberculosis prevention by the WHO. We identified male 
gender, low body weight, glucocorticoid therapy and diabe-
tes mellitus as risk factors for tuberculosis. Risk factors for 
LTBI included sexual relationship to a diseased household 
partner and substance abuse. Among HCWs, only long-
term professional exposure to tuberculosis patients was 
related to LTBI. Despite a high frequency of positive IGRA 
test results among HHCs and HCWs no contact developed 
active tuberculosis during a 2-year follow-up period.
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